- General Drug Summary
- Description
- A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem]
- Also Known As
- (2S)-2-Aminopropanoic acid; (S)-(+)-Alanine; (S)-2-Aminopropanoic acid; (S)-Alanine; 2-Aminopropanoic acid; 2-Aminopropionic acid; a-Alanine; a-Aminopropionic acid; ALA; Alanine; L-(+)-Alanine; L-2-Aminopropanoic acid; L-2-Aminopropionic acid; L-a-Alanine; L-a-Aminopropionic acid
- Categories
- Non-Essential Amino
- Groups
- approved; nutraceutical
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for L-Alanine NA in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 16297302
- L-Alanine
- NA
- Clinical Trial
- Summary
- Compared with the unconjugated group, the conjugated hyperbilirubinaemia group had statistically significantly higher aspartate aminotransferase and alanine aminotransferase
- Urinary tract infections in infants: comparison between those with conjugated vs unconjugated hyperbilirubinaemia. Annals of tropical paediatrics, 2005 Dec [Go to PubMed]
- The aim was to investigate conjugated and unconjugated hyperbilirubinaemia in association with urinary tract infection (UTI) in young infants.
Fifty infants aged <3 mths who developed prolonged jaundice among 2128 infants with UTI from 1984 to 2004 were enrolled retrospectively. They were divided into conjugated (n=22) and unconjugated (n=28) hyperbilirubinaemia groups and the clinical variables between the two were compared.
Compared with the unconjugated group, the conjugated hyperbilirubinaemia group had statistically significantly lower haemoglobin (1.57 vs 1.80 micromol/L), higher aspartate aminotransferase (96 vs 32.5 U/L) and alanine aminotransferase (81.5 vs 16 U/L), were older on admission (48.0 vs 32.5 days), had a longer duration of jaundice before treatment (43.5 vs 30 days) and a higher incidence of E. coli infections (19/22 vs 15/28). The direct/total bilirubin ratio was linearly correlated with duration of jaundice before treatment (p=0.004). The most significant cut-off value for the duration of jaundice vis-à-vis the type of jaundice was 38 days (p=0.007). Patients who on presentation had had jaundice for >44 days (p=0.007) were unlikely to have unconjugated hyperbilirubinaemia.
Infants with UTI may present with unconjugated hyperbilirubinaemia in the early stage. After 6 weeks, it is always conjugated hyperbilirubinaemia and is frequently associated with anaemia, elevated hepatic aminotransferases and E. coli infections.